🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07615530
Starting soon Not applicable

Positive Expectation Effects on Early Emotional Processing

NCT07615530 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2026-06
Last updated
2026-06-02

Condition(s) studied

Positive Expectations

Investigational drug(s) / intervention(s)

Saline Nasal SpraySaline Nasal Spray

Saline Nasal Spray: A saline nasal spray will be introduced as oxytocin on the first day (induced positive expectations) and as saline on the second day (no induced expectations)

Saline Nasal Spray: A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)

Study summary

Insights into the mechanisms of expectation effects in the emotional domain can be invaluable for the development of potential therapeutic interventions for mood disorders. Recent findings demonstrate that positive expectations alone can induce a positivity bias on the behavioral and the neural level (Baker et al.,2022, Mostauli et al., 2025). This is intriguing given that antidepressant treatments, which have high placebo rates are reported to reduce a negativity bias commonly observed in depression.

Research on placebo analgesia has shown that both higher-order cognitive expectations and lower-level learning mechanisms, such as conditioning, play a key role in placebo effects. The role of such lower-level processes is particularly underexplored in affective placebo effects. Closing this gap is crucial, as the long-term modulation of the emotional system likely depends on cognitively less demanding, bottom-up processes shaped by learning and conditioning. This is particularly relevant in clinical populations, where cognitive resources may be limited, but there is an abundance of prior experiences (i.e., learning).

The present study therefore investigates how treatment expectations influence early psychophysiological processing of emotional stimuli. Beyond behavioral measures, we will directly assess early neural and attentional mechanisms using sensory event-related potentials (ERPs) and reflexive gaze shifts. By combining EEG and eye-tracking, we aim to identify early markers of expectation effects during emotional processing in healthy participants (N=44 plus 15% potential dropout, 50% women), who perform an emotion classification task. Emotional faces will be presented at varied levels of stimulus visibility (alpha transparency), allowing us to model perceptual sensitivity and response bias without inducing ceiling effects.

Treatment expectation will be induced by verbal instructions using an established protocol (e.g. Baker et al., 2022, Mostauli et al., 2025). We hypothesize that positive expectations enhance mood and decrease reaction times paralleled by better accuracy. Further, we hypothesize that positive treatment expectation enhances gaze shifts toward the mouth region which is the primary diagnostic feature for happy faces. On the neural level we expect that positive expectations modulate EEG signal patterns associated with early emotional valence processing. Additionally, whole-brain and time-frequency analyses, as well as representational similarity analyses, are planned to further explore into neural expectation effects and potential changes in the hierarchical representation of emotional processing.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Aged 18-35 years * Normal or corrected to normal vision * Signed declaration of consent * German speaking Exclusion Criteria: * No informed consent * Current intake of central nervous system active drugs * Under influence of alcohol * BDI score above 12 * Significant acute somatic or neurological diseases * History of psychiatric or neurological disorders * Acute nasal diseases or injuries * EEG data with strong artefacts or excessive movement will be excluded from analysis * If a participant does not believe in the treatment on the screening day, they will not be included for the main study days

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Medical Center Hamburg-Eppendorf, Institute of Systems Neuroscience Hamburg Free and Hanseatic City of Hamburg

More Universitätsklinikum Hamburg-Eppendorf trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07615530 on ClinicalTrials.gov ↗ ← All trials in Germany